Kodiak Sciences $645 million follow-on offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $645.0 million public offering of 5,972,222 shares of common stock by…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Five Prime Therapeutics $173 million follow-on offering
Davis Polk advised the joint-bookrunning managers and representatives of the several underwriters in connection with an approximately $173.8 million public offering of common stock by…
Bristol Myers Squibb $7 billion notes offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with an SEC-registered public debt offering by Bristol-Myers Squibb Company,…
BioNTech $500 million SEC-registered at-the-market offering
Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by BioNTech SE of its ordinary shares represented by American depositary shares for up to an…
Affimed $75 million SEC-registered at-the-market offering program
Davis Polk advised the sales agent in connection with the establishment of an SEC-registered at-the-market offering program by Affimed N.V. of up to $75 million gross sales price of…
RemeGen HK$4 billion Hong Kong IPO
Davis Polk advised the underwriters in the initial public offering of RemeGen Co., Ltd. on the Hong Kong Stock Exchange and an international offering and listing in reliance on Rule 144A…
NovoCure $575 million convertible senior notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by NovoCure Limited of $575 million aggregate principal amount of its 0.000%…
JW (Cayman) Therapeutics HK$2.33 billion Hong Kong IPO
Davis Polk advised the underwriters in the initial public offering of JW (Cayman) Therapeutics Co. Ltd on the Hong Kong Stock Exchange and an international offering and listing in reliance…
Atea Pharmaceuticals $345 million IPO
Davis Polk advised the representatives of the underwriters in connection with the $345 million initial public offering of 14,375,000 shares of common stock of Atea Pharmaceuticals, Inc.,…
Allakos $272 million follow-on offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the follow-on offering of 3,506,098 shares of common stock of Allakos Inc…